Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of ACT-1014-6470 with Omeprazole and Midazolam
NCT05123820Phase 1Completed
- Sponsor
- Idorsia
- Start
- Nov 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ACT-1014-6470 in immune-mediated inflammatory diseases (IMIDs), sponsored by Idorsia. Primary endpoints: Maximum plasma concentration up to 11 days, Time to reach Cmax up to 11 days and 6 more. Started Nov 2021; status: completed.
02
Drugs
ACT-1014-6470
03
Conditions
immune-mediated inflammatory diseases (IMIDs)
Beyond the preview
Go deeper on NCT05123820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05123820.